WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004032914) USE OF A PROPARGYL ALCOHOL ENANTIOMER FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/032914    International Application No.:    PCT/EP2003/008624
Publication Date: 22.04.2004 International Filing Date: 04.08.2003
Chapter 2 Demand Filed:    24.02.2004    
IPC:
A61K 31/192 (2006.01)
Applicants: GALDERMA RESEARCH & DEVELOPMENT, S.N.C. [FR/FR]; 635, route des Lucioles, Quartier des Clausonnes, F-06560 Valbonne Sophia Antipolis (FR) (For All Designated States Except US).
CARON, Jean-Claude [FR/FR]; (FR) (For US Only)
Inventors: CARON, Jean-Claude; (FR)
Agent: L'OREAL; Christophe Andral - D.I.P.I., 25-29, quai Aulagnier, F-92600 Asnières (FR)
Priority Data:
0210412 20.08.2002 FR
60/405,721 26.08.2002 US
Title (EN) USE OF A PROPARGYL ALCOHOL ENANTIOMER FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
(FR) UTILISATION D'UN ENANTIOMERE D'ALCOOL PROPARGYLIQUE
Abstract: front page image
(EN)The invention relates to the specific use of a pure enantiomer of 2-hydroxy-4- [3-hydroxy-3- (5,6,7,8tetrahydro-5,5,8,8­tetramethyl-2-naphthyl)-1propynyl] benzoic acid in the S (+) configuration, of formula (I) below: or one of its salts, for preparing a pharmaceutical composition intended for use in human and/or veterinary medicine. The present invention also relates to a pharmaceutical composition comprising, in a physiologically acceptable carrier, at leas2-hydroxy4-[3-hydroxy-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl 2-naphthyl)-1-propynyl] benzoic acid in the S (+) configuration, of formula (I), or one of its salts.
(FR)Cette invention a trait à l'utilisation spécifique d'un énantiomère pur d'acide benzoïque-2-hydroxy-4- [3-hydroxy-3- (5,6,7,8tétrahydro-5,5,8,8-tétramethyl-2-naphthyl)-1propynyl] dans la configuration S (+), correspondant à la formule ci-dessous, ou à l'un de ses sels, et ce, pour préparer une composition pharmaceutique destiné à la médecine humaine ou vétérinaire. Elle porte également sur une composition pharmaceutique renfermant, dans un excipient acceptable du point de vue physiologique, au moins un acide benzoïque-2-hydroxy-4-[3-hydroxy-3-(5,6,7,8-tétrahydro-5,5,8,8-tétramethyl 2-naphthyl)-1-propynyl] dans la configuration S (+), correspondant à la formule (I), ou à l'un de ses sels.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)